A Phase 1 interventional study of BMS-986177 in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-10.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other
Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.
1,506 studies on the registry are indexed under Thrombosis; 238 are open to participants now.
This study's enrollment of 24 is below the median of 106 across 849 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria could apply
Normal Renal Function
Drug: BMS-986177
Moderate Renal Impairment
Drug: BMS-986177
Severe Renal Impairment
Drug: BMS-986177
Oral Suspension
Maximum observed plasma concentration (Cmax)
Measured by plasma concentration
Time frame: Up to 5 days
AUC from time zero to time of last quantifiable concentration (AUC (0-T))
Summary measures of PK parameters
Time frame: Up to 5 days
AUC from time zero extrapolated to infinite time (AUC (INF))
Summary measures of PK parameters
Time frame: Up to 5 days
Incidence of Adverse Events (AEs)
Safety and tolerability as measured by incidence of AEs
Time frame: Up to 5 days
Incidence of Serious Adverse Events ( SAEs)
Safety and tolerability as measured by incidence of SAEs
Time frame: Up to 30 days
Change from baseline in electrocardiogram findings
Measured by investigator assessment
Time frame: Up to 5 days
Change from baseline in physical examination findings
Measured by investigator assessment
Time frame: Up to 5 days
Change from baseline in clinical laboratory test findings
Measured by investigator assessment
Time frame: Up to 5 days
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb